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Summary. There is a wealth of evidence that non- 
steroidal anti-inflammatory drugs (NSAIDs) can prevent 
colorectal cancer. In this article the role of cyclo- 
oxygenase 1 and 2, the principle target of NSAIDs, in 
the development of colorectal cancer is reviewed. 
Cyclooxygenase is constituitevely expressed in normal 
colonic epithelium and surrounding stroma and could 
catalyse the generation of malondialdehyde which is a 
known mutagen and could initiate colorectal carcino- 
genesis. Mutation of APC which is an early genetic 
event leads to the expression of cyclooxygenase 2 which 
may prevents the appropriate apoptosis of mutant 
adenoma cells. Other proneoplastic effects of cyclo- 
oxygenase include changing the action of Transforming 
Growth Factor l3 from anti-proliferative to pro- 
proliferative, reducing adherence to extracellular matrix, 
promotes metastasis and angiogenesis. These properties 
of cyclooxygenases suggest that inhibition of both 
isoforms may have important protective effects against 
colorectal cancer. 
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Introduction 
There has been much interest in prevention of 
colorectal cancer in recent years. Current strategies 
depend on either dietary modification (Bingham, 1996), 
removal of adenomatous polyps (Winawer et al., 1997), 
detection of oncogene products in stool (Sidransky et al., 
1992) or use of non-steroidal anti-inflammatory drugs 
(NSAIDs). In this article the rationale and mechanism of 
action of NSAIDs in the prevention of colorectal cancer 
will be reviewed paying particular attention to the role of 
cyclooxygenase isoenzymes, their principle therapeutic 
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target. 
Evidence that NSAlDs prevent colorectal cancer 
There are three lines of evidence that NSAIDs 
prevent colorectal cancer. First a number of animal 
studies have shown that a variety of NSAIDs, including 
sulindac (Rao et al., 1995), piroxicam (Reddy et al., 
1987) and aspirin (Reddy et al., 1993) can prevent 
chemically-induced cancer in rodents. The degree of 
reduction in tumour burden in these studies was 
sometimes as high as 60% and was associated with a 
substantial reduction i n  the tissue concentration of 
eicosanoid products. 
The second line of evidence is that NSAIDs can 
reduce the number and size of polyps in patients with 
familial adenomatous polyposis (FAP). FAP is an 
autosomal dominant condition resulting from mutations 
in the adenomatous polyposis coli gene which located on 
chromosome 5q21 which inevitably results in colorectal 
cancer by the age of 40 (Kinzler et al., 1991). The 
original observation by Waddell and colleagues in 1983 
that sulindac reduced the number polyps in FAP patients 
has been confirmed by a number of studies including 
two double-blinded, randomised placebo-controlled trial 
of sulindac (Waddell and Loughry, 1983; Labayle et al., 
1991; Giardiello et al., 1993). 
However the most compelling comes from prospect- 
ive cohort studies of the development of spontaneous 
colorectal cancer. In a cohort of over one million persons 
men who used more aspirin more than 16 times a month 
had a relative risk of developing colorectal cancer of 
0.48 (0.30-0.76) and women a relative risk of 0.53 (0.32- 
0.87) (Thun et al., 1991). In a later prospective cohort 
prospective clinical studies of non-medical health care 
workers between ages 40 and 75 who regularly and 
consistently tool aspirin had a relative risk of 0.35 (0.16- 
0.75) (Giovannucci et al., 1994). An important aspect of 
this study was that prior use of endoscopic evaluation of 
the colon and other confounders were controlled for by 
multivariate analysis. In a further cohort study of 89,446 






